DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0203043 A1 Rusch Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0203043 A1 Rusch Et Al US 20170203043A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0203043 A1 Rusch et al. (43) Pub. Date: Jul. 20, 2017 (54) MEDICAL DELIVERY DEVICE WITH (52) U.S. Cl. LAMINATED STOPPER CPC ....... A61M 5/31505 (2013.01); A6IL 31/048 (2013.01); A61M 2005/3101 (2013.01) (71) Applicant: W. L. Gore & Associates, Inc., Newark, DE (US) (72) Inventors: Greg Rusch, Newark, DE (US); (57) ABSTRACT Robert C. Basham, Forest Hill, MD (US) The present disclosure relates to a medical delivery device (21) Appl. No.: 15/404,892 that includes a barrel having an inner Surface, a plunger rod having a distal end inserted within the barrel, and a stopper (22) Filed: Jan. 12, 2017 attached to the distal end of the plunger rod and contacting at least a portion of the inner surface of the barrel. In at least Related U.S. Application Data one embodiment, the inner surface is hydrophilic. The (60) Provisional application No. 62/279,553, filed on Jan. stopper may include an elastomeric body, one or more 15, 2016. fluoropolymer layers, and two or more ribs laminated with the one or more fluoropolymer layers. In some embodi Publication Classification ments, the contact width between at least one rib having a (51) Int. Cl. sealing Surface and the portion of the inner Surface of the A6M 5/35 (2006.01) barrel measured at a compressibility of greater than about A6IL 3L/04 (2006.01) 7.9% of the stopper is less than about 1.0 mm. O y 95 25 85 105 0 Patent Application Publication Jul. 20, 2017 Sheet 1 of 6 US 2017/0203043 A1 1.O. : W. W. 70 95 2s. 85 105 do y 3S 2 FG, Patent Application Publication Jul. 20, 2017 Sheet 2 of 6 US 2017/0203043 A1 FG, 2 FG 3 Patent Application Publication Jul. 20, 2017 Sheet 3 of 6 US 2017/0203043 A1 5 FG, 5 Patent Application Publication Jul. 20, 2017 Sheet 4 of 6 US 2017/0203043 A1 FG, 8 170 Patent Application Publication Jul. 20, 2017 Sheet 5 of 6 US 2017/0203043 A1 Patent Application Publication Jul. 20, 2017 Sheet 6 of 6 US 2017/0203043 A1 FG, OA FG, OB US 2017/0203043 A1 Jul. 20, 2017 MEDICAL DELIVERY DEVICE WITH Surface of a barrel of a glass or resin Syringe to achieve high LAMINATED STOPPER levels of air and liquid impermeability while also maintain ing acceptably low break loose and slide forces (i.e., low FIELD friction slidability) but not so much contact that the fluo ropolymer film is distorted to create leak paths that decrease 0001. The present invention relates to a medical delivery air and liquid impermeability. device with a laminated stopper, and in particular, to a medical delivery device with a stopper laminated with a fluoropolymer film. SUMMARY 0006. One embodiment relates to a medical delivery BACKGROUND device that includes a barrel, a plunger rod having a distal 0002 Medical delivery devices such as syringes typically end inserted within the barrel, a stopper attached to the distal include a barrel, a plunger rod reciprocally movable in the end of the plunger rod and contacting at least a portion of the barrel, and a stopper attached to an end of the plunger rod. inner surface of the barrel. The stopper has an elastomeric The stopper to be used for the Syringe is typically air, and body, one or more fluoropolymer layers, and two or more liquid impermeable while also possessing low-friction slid ribs laminated with the one or more fluoropolymer layers. A ability. Air and liquid impermeability is important for elimi contact width between at least one of the two or more ribs nating liquid leakage within the barrel and the introduction having a sealing Surface and a portion of the inner Surface of of air between an outer face of the stopper and an inner wall the barrel measured at a compressibility of greater than of the barrel when charging or discharging the liquid inside about 7.9% of the stopper is less than about 1.0 mm. In at the syringe. Low-friction slidability is important for facili least one embodiment, the barrel has a hydrophilic inner tating the charging and discharging of the liquid inside the surface. Optionally, the hydrophilic inner surface is bare Syringe. In addition to these requirements, a medical glass (e.g., free or Substantially free of silicone oil). Syringe, in particular, must not, adversely affect any phar 0007. In some embodiments, the medical delivery device maceutical composition Such as biopharmaceuticals that further includes a sliding surface that is less than about 2.0 come in contact with the Syringe (e.g., a pre-filled Syringe mm, which is calculated based on a sum of the contact comprising a pharmaceutical composition). widths between at least one of the two or more ribs having 0003 Stoppers for conventional syringes are commonly a sealing Surface and the portion of the inner Surface of the made of a rubber material such as natural rubber, isoprene barrel measured at a compressibility of greater than about rubber or styrene-butadiene rubber which may be vulca 7.9%. nized. Although this type of conventional stopper, has sat 0008. In some embodiments, at least one of each rib of isfactory air and liquid impermeability, it does not have good the two or more ribs having a sealing Surface includes a low-friction slidability. Accordingly, silicone lubricants are radius of curvature at an apex of each respective rib that is typically applied to both the outerface of the stopper and the less than about 0.22 mm; and a ratio of a maximum outer inner wall of the barrel such that the stopper can slide within diameter of all the ribs having a sealing Surface to an inner the barrel. However, Syringes comprising silicone lubricants diameter of the inner surface of the barrel is nominally cannot be used for pharmaceutical composition and the like greater than about 1.08. because the silicone lubricant can cause inactivation or 0009. In some embodiments, a maximum outer diameter otherwise impact the efficacy of these pharmaceutical com of the ribs having a sealing Surface is greater than about 5.0 positions. Therefore, in order to maintain the stability of the mm, an inner diameter of the inner surface of the barrel is pharmaceutical composition, stoppers laminated with a fluo nominally between about 4.65 and about 11.85 mm, and a ropolymer film have been used. Since the air and liquid ratio of the maximum outer diameter of the ribs having a impermeability of stoppers may also have an impact on the sealing Surface to an inner diameter of the inner Surface of quality and stability of the pharmaceutical compositions, the the barrel is greater than about 1.08. stoppers laminated with a fluoropolymer film are required to 0010. In another embodiment, a plunger rod includes a have high levels of air and liquid impermeability. However, distal end that is insertable into a barrel and a stopper when stoppers laminated with a fluoropolymer film are used attached to the distal end. In one or more embodiment, the with a glass or resin Syringe having a hydrophilic or lubri barrel has a hydrophilic inner Surface. The stopper is con cant free inner surface, the stoppers undesirably exhibit figured to contact at least a portion of the inner Surface of the poorer air and liquid impermeability than conventional, barrel. The stopper includes an elastomeric body, one or non-laminated rubber stoppers. more fluoropolymer layers, and two or more ribs laminated 0004 Another problem associated with some fluoropo with the one or more fluoropolymer layers. Each rib of the lymer laminates is its ability to maintain air and liquid two or more ribs having a sealing Surface includes a radius impermeability while also possessing low-friction slidabil of curvature at an apex of each respective rib that is less than ity. For example, Some fluoropolymer laminates function about 0.22 mm, and a ratio of a maximum outer diameter of inconsistently and can distort during insertion of the plunger all the ribs having a sealing Surface to an inner diameter of rod into the barrel and/or during movement of the plunger the inner surface of the barrel is greater than about 1.08. The rod within the barrel, which can create leak paths for the plunger rod may be configured such that when the plunger liquid. Additional difficulties with some fluoropolymer lami rod is inserted in the barrel having an inner diameter of an nates include poor airtightness due to a rough outer Surface inner surface of the barrel, a contact width between at least especially when manufactured as a skived film. one of the two or more ribs having a sealing Surface and the 0005 Accordingly, the need exists for stoppers laminated portion of the inner surface of the barrel measured at a with a fluoropolymer film that are capable of achieving compressibility of greater than about 7.9% of the stopper is sufficient contact with a hydrophilic or lubricant free inner less than about 1.0 mm. US 2017/0203043 A1 Jul. 20, 2017 0011. In yet another embodiment, a stopper that is insert lymer laminates have good biocompatibility, have good able in a barrel having a hydrophilic inner Surface comprises mechanical integrity, are inert, and are processable. an elastomeric body, one or more fluoropolymer layers, and 0020. In some embodiments, the stopper has a compress two or more ribs. The at least one of the two or more ribs are ibility (C96) that is greater than about 7.9%, between about laminated with the one or more fluoropolymer layers and 9.5 and about 20.0%, between about 11.75 and about 18.5%, configured to contact at least a portion of the inner Surface between about 14.0 and about 14.5.
Load more

Recommended publications
  • Depatuxizumab Mafodotin (ABT-414)
    Published OnlineFirst May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-0609 MOLECULAR CANCER THERAPEUTICS | CANCER BIOLOGY AND TRANSLATIONAL STUDIES Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation Caroline von Achenbach1, Manuela Silginer1, Vincent Blot2, William A. Weiss3, and Michael Weller1 ABSTRACT ◥ Glioblastomas commonly (40%) exhibit epidermal growth factor Exposure to ABT-414 in vivo eliminated EGFRvIII-expressing receptor EGFR amplification; half of these tumors carry the EGFR- tumor cells, and recurrent tumors were devoid of EGFRvIII vIII deletion variant characterized by an in-frame deletion of exons expression. There is no bystander killing of cells devoid of EGFR 2–7, resulting in constitutive EGFR activation. Although EGFR expression. Surprisingly, either exposure to EGF or to EGFR tyrosine kinase inhibitors had only modest effects in glioblastoma, tyrosin kinase inhibitors reduce EGFR protein levels and are thus novel therapeutic agents targeting amplified EGFR or EGFRvIII not strategies to promote ABT-414–induced cell killing. Further- continue to be developed. more, glioma cells overexpressing kinase-dead EGFR or EGFR- Depatuxizumab mafodotin (ABT-414) is an EGFR-targeting vIII retain binding of mAb 806 and sensitivity to ABT-414, antibody–drug conjugate consisting of the mAb 806 and a toxic allowing to dissociate EGFR phosphorylation from the emer- payload, monomethyl auristatin F. Because glioma cell lines and gence of the “active” EGFR conformation required for ABT-414 patient-derived glioma-initiating cell models expressed too little binding. EGFR in vitro to be ABT-414–sensitive, we generated glioma The combination of EGFR-targeting antibody–drug conju- sublines overexpressing EGFR or EGFRvIII to explore determinants gates with EGFR tyrosine kinase inhibitors carries a high risk of ABT-414–induced cell death.
    [Show full text]
  • Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors
    Cancer Biol Med 2021. doi: 10.20892/j.issn.2095-3941.2020.0704 REVIEW Strategies to enhance monoclonal antibody uptake and distribution in solid tumors Brandon M. Bordeau, Joseph P. Balthasar Department of Pharmaceutical Science, University at Buffalo, Buffalo, NY 14214, USA ABSTRACT Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vasculature and a dense extracellular matrix that slow both the convective and diffusive transport of mAbs into and within tumors. For mAbs that are directed against cellular antigens, high antigen expression and rapid antigen turnover can result in perivascular cells binding to and eliminating a significant amount of extravasated mAb, limiting mAb distribution to portions of the tumor that are distant from functional vessels. Many preclinical investigations have reported strategies to improve mAb uptake and distribution; however, to our knowledge, none have translated into the clinic. Here, we provide an overview of several barriers in solid tumors that limit mAb uptake and distribution and discuss approaches that have been utilized to overcome these barriers in preclinical studies. KEYWORDS Solid tumors; antibody uptake and distribution; monoclonal antibody; antibody–drug conjugate Introduction Currently, monoclonal antibodies (mAbs) are heralded as the “magic bullets” that Ehrlich envisioned, and in many cases, the In 1900, Paul Ehrlich developed the receptor theory, which moniker is well deserved. Antibodies can bind most substances was built on the foundational hypothesis that toxins, nutri- with high affinity and high selectivity and are used for the treat- ents, and drugs exert their observed effect through binding to ment of many diseases.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
    Figure 1. This is a pilot view to explore the potential of EpiGraphDB to inform us about proteins that are linked to the pathophysiology of cancer and cardiovascular disease (CVD). For each cancer type (pink diamonds), we searched for cancer related proteins (light blue circles) that interact with other proteins identified as protein quantitative trait loci (pQTLs) for CVD (red diamonds for pathologies, orange triangles for risk factors). These pQTLs can be acting in cis (solid lines) or trans-acting (dotted lines). Proteins can interact either directly, a protein-protein interaction (dotted blue edges), or through the participation in the same pathway (red parallel lines). Shared pathways are represented with blue hexagons. We also queried which of these proteins are targeted by existing drugs. We found that the cancer drug cetuximab (yellow circle) inhibits EGFR. Other potential drugs are depicted in light brown hexagonal meta-nodes that are detailed below. Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology Pau Erola1,2, Benjamin Elsworth1,2, Yi Liu2, Valeriia Haberland2 and Tom R Gaunt1,2,3 1 CRUK Integrative Cancer Epidemiology Programme; 2 MRC Integrative Epidemiology Unit, University of Bristol; 3 The Alan Turing Institute Cancer and cardiovascular disease (CVD) make by far the immense What is EpiGraphDB? contribution to the totality of human disease burden, and although mortality EpiGraphDB is an analytical platform and graph database that aims to is declining the number of those living with the disease shows little address the necessity of innovative and scalable approaches to harness evidence of change (Bhatnagar et al., Heart, 2016).
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Development of Red Blood Cell Autoantibodies Following Treatment with Checkpoint Inhibitors
    CASE R EP O RT Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation L.L.W. Cooling, J. Sherbeck, J.C. Mowers, and S.L. Hugan Ipilimumab, nivolumab, and pembrolizumab represent a new Table 1. Checkpoint inhibitors class of immunotherapeutic drugs for treating patients with Drug class (trade name, manufacturer) advanced cancer. Known as checkpoint inhibitors, these drugs act to upregulate the cellular and humoral immune response Anti-CTLA-4 to tumor antigens by inhibiting T-cell autoregulation. As a Ipilimumab (Yervoy, Bristol-Myers Squibb) consequence, they can be associated with immune-related adverse Tremelimumab (AstraZeneca, compassionate use only) events (irAEs) due to loss of self-tolerance, including rare cases of immune-related cytopenias. We performed a retrospective Anti-PD-1 clinical chart review, including serologic, hematology, and Nivolumab (Opdivo, Bristol-Myers Squibb) chemistry laboratory results, of two patients who developed Pembrolizumab (Keytruda, Merck Sharp & Dohme) red blood cell (RBC) autoantibodies during treatment with a Pidilizumab (Medivations, in clinical trials) checkpoint inhibitor. Serologic testing of blood samples from these patients during induction therapy with ipilimumab and Anti-PD-L1 nivolumab, respectively, showed their RBCs to be positive by Atezolizumab (Genentech, in clinical trials) the direct antiglobulin test (IgG+, C3+) and their plasma to Durvalumab (AstraZeneca, approved bladder cancer) contain panreactive RBC autoantibodies. Neither patient had evidence of hemolysis. Both patients developed an additional CTLA-4 = cytotoxic T-lymphocyte–associated antigen 4; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Caries Vaccine: an Overview Dr
    Saudi Journal of Oral and Dental Research Abbreviated Key Title: Saudi J Oral Dent Res ISSN 2518-1300 (Print) |ISSN 2518-1297 (Online) Scholars Middle East Publishers, Dubai, United Arab Emirates Journal homepage: https://saudijournals.com/sjodr Review Article Caries Vaccine: An Overview Dr. Charvi Gupta*, Dr. Hemant Mankel Assistant Professor, Mekelle University, Ethiopia DOI: 10.36348/sjodr.2020.v05i05.003 | Received: 13.05.2020 | Accepted: 20.05.2020 | Published: 23.05.2020 *Corresponding author: Dr. Charvi Gupta Abstract One of the most common diseases in humans is dental caries. It is an infectious disease of microbiological origin that results in localized dissolution and destruction of the calcified tissue of teeth. It is a diseased caused by multitude of factors like host, agent and environmental factors. Microbes like S. mutans, Lactobacillus acidophilus and Actinomyces viscosus are the main pathogenic species involved with initiation and progression of dental caries. Indian surveys demonstrate caries prevalence of 58% in school children. Among the U.S. Population surveys showed 45.3% children and 93.8% of adults. A large costing of dental treatments whether prevention using remineralizing agents and treatment using restorative materials can be reduced if we could eradicate dental caries completely. Thus the ultimate objective of community health is the complete elimination of this disease. Development of dental caries vaccines is a boon for eradication of this microbiological disease. Keywords: Dental caries, infectious disease, microbes, S.mutans, prevention, dental caries vaccines. Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.
    [Show full text]
  • IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
    61 1 Journal of Molecular C Mancarella and Targeting IGF system in sarcoma 61:1 T45–T60 Endocrinology K Scotlandi THEMATIC REVIEW 40 YEARS OF IGF1 IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy Caterina Mancarella and Katia Scotlandi Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy Correspondence should be addressed to K Scotlandi: [email protected] This paper forms part of a special section on 40 Years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher. Abstract The insulin-like growth factor (IGF) system has gained substantial interest due to its Key Words involvement in regulating cell proliferation, differentiation and survival during anoikis f sarcomas and after conventional and targeted therapies. However, results from clinical trials have f IGF system been largely disappointing, with only a few but notable exceptions, such as trials targeting f targeted therapy sarcomas, especially Ewing sarcoma. This review highlights key studies focusing on IGF f clinical trials signaling in sarcomas, specifically studies underscoring the properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. This review discusses the potential roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs) and metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) in regulating the IGF system. Deeper investigation of these novel regulators of the IGF system may help us to further elucidate the spatial and temporal control of the IGF Journal of Molecular axis, as understanding the control of this axis is essential for future clinical studies.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH
    Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0555 Research Article Molecular Cancer Therapeutics A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts Yaolin Wang1, Philip Lipari1, Xiaoying Wang1, Judith Hailey1, Lianzhu Liang1, Robert Ramos1, Ming Liu1, Jonathan A. Pachter2, W. Robert Bishop1, and Yan Wang1 Abstract The insulin-like growth factor-I receptor (IGF-IR) and its ligands (IGF-I and IGF-II) have been implicated in the growth, survival, and metastasis of a broad range of malignancies including pediatric tumors. Blocking the IGF-IR action is a potential cancer treatment. A fully human neutralizing monoclonal antibody, SCH 717454 (19D12, robatumumab), specific to IGF-IR, has shown potent antitumor effects in ovarian cancer in vitro and in vivo. In this study, SCH 717454 was evaluated in several pediatric solid tumors including neuroblastoma, osteosarcoma, and rhabdomyosarcoma. SCH 717454 is shown here to downregulate IGF-IR as well as inhibit IGF-IR and insulin receptor substrate-1 phosphorylation in pediatric tumor cells. IGF-IR and insulin receptor substrate-1 phosphorylation in the tumor cells. In vivo, SCH 717454 exhibits activity as a single agent and sig- nificantly inhibited growth of neuroblastoma, osteosarcoma, and rhabdomyosarcoma tumor xenografts. Combination of SCH 717454 with cisplatin or cyclophosphamide enhanced both the degree and the duration of the in vivo antitumor activity compared with single-agent treatments. Furthermore, SCH 717454 treatment markedly reduced Ki-67 expression and blood vessel formation in tumor xenografts, showing that the in vivo activity is derived from its inhibition of tumor cell proliferation and angiogenesis activity.
    [Show full text]